DRD2 Gene

DRD2 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">DRD2 — Dopamine Receptor D2</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>DRD2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Dopamine Receptor D2</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>11q23.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/1819" target="_blank">1819</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000149295" target="_blank">ENSG00000149295</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P14416" target="_blank">P14416</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Parkinson's Disease](/diseases/parkinsons-disease), [Schizophrenia](/diseases/schizophrenia), [Parkinsonism](/diseases/parkinsonism)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Striatum, Substantia nigra, Pituitary, [Cortex](/brain-regions/cortex)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cardiac" style="color:#ef9a9a">Cardiac</a>, <a href="/wiki/depression" style="color:#ef9a9a">Depression</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a h

DRD2 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">DRD2 — Dopamine Receptor D2</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>DRD2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Dopamine Receptor D2</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>11q23.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/1819" target="_blank">1819</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000149295" target="_blank">ENSG00000149295</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P14416" target="_blank">P14416</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Parkinson's Disease](/diseases/parkinsons-disease), [Schizophrenia](/diseases/schizophrenia), [Parkinsonism](/diseases/parkinsonism)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Striatum, Substantia nigra, Pituitary, [Cortex](/brain-regions/cortex)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cardiac" style="color:#ef9a9a">Cardiac</a>, <a href="/wiki/depression" style="color:#ef9a9a">Depression</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">231 edges</a></td>
</tr>
</table>

DRD2 — Dopamine Receptor D2

Pathway Diagram

Introduction

Drd2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

DRD2 (Dopamine Receptor D2) encodes the D2 dopamine receptor, a G protein-coupled receptor that inhibits adenylyl cyclase and reduces intracellular cAMP. It functions as both a presynaptic autoreceptor and postsynaptic receptor, critical for motor control, reward, and prolactin regulation[@beaulieu2011].

Function

Signaling

• Gi/o coupling: Inhibits adenylyl cyclase
• Reduced cAMP: Decreases PKA activity
• Beta-arrestin pathways: G protein-independent signaling
• GIRK channel activation: Hyperpolarization through potassium channels
• PI3K/Akt pathway: Anti-apoptotic signaling

Brain Functions

• Motor inhibition: Indirect pathway in basal ganglia[@drd2_striatum]
• Reward: Modulates dopaminergic tone
• Presynaptic autoreceptor: Regulates dopamine release[@drd2_autoreceptor]
• Motor learning: Procedural memory formation
• Endocrine control: Prolactin inhibition[@drd2_prolactin]

Pre- vs Postsynaptic Localization

Presynaptic D2 receptors (autoreceptors):

• Located on dopamine neuron terminals
• Detect ambient dopamine levels
• Inhibit dopamine release (negative feedback)
• Regulate firing rate through somatodendritic signaling
• Lower affinity for dopamine than postsynaptic receptors

• Located on indirect pathway striatal neurons
• Also on cortex, hippocampus, amygdala
• Mediate motor inhibition and reward modulation
• Different isoforms: D2S (short) and D2L (long)

Disease Associations

Parkinson's Disease

• Primary therapeutic target for motor symptoms
• D2 agonists (ropinirole, pramipexole, rotigotine)
• Levodopa works through D2 receptors

Schizophrenia

• D2 receptor blockade by antipsychotics
• D2 hypersensitivity theory
• Most antipsychotics are D2 antagonists

Prolactinomas

• D2 receptors inhibit prolactin secretion
• D2 agonists treat hyperprolactinemia

Alzheimer's Disease

• D2 receptor expression changes in AD
• Interactions with cholinergic system
• Cognitive effects of D2 modulation
• Potential for neuropsychiatric symptoms

Huntington's Disease

• Early loss of D2 receptors
• Contributes to motor dysfunction
• D2 agonist trials in HD

Neurodegeneration Mechanisms

Dopamine Signaling Dysregulation

• Loss of D2 autoreceptor function leads to excessive dopamine release
• Excitotoxic vulnerability from dysregulated neurotransmission
• Oxidative stress from dopamine metabolism

Receptor Trafficking

• D2 receptor internalization in PD
• Altered desensitization patterns
• Impaired receptor recycling

Neuroinflammation

• D2 receptors on microglia
• Anti-inflammatory effects of D2 activation
• Therapeutic implications for PD

Protein Isoforms

D2S (Short) isoform

• Predominantly presynaptic
• Functions as autoreceptor
• Alternative splicing creates isoforms

D2L (Long) isoform

• Predominantly postsynaptic
• Mediates motor inhibition
• Expressed in striatum

Therapeutic Targeting

Parkinson's Disease

• D2 Agonists: Ropinirole, Pramipexole, Rotigotine, Apomorphine
• Dopamine Replacement: Levodopa (converted to dopamine, activates D2)
• COMT Inhibitors: Entacapone, Opicapone (prolong levodopa effect)

Schizophrenia

• First-generation: Haloperidol, Chlorpromazine
• Second-generation: Risperidone, Olanzapine, Quetiapine, Aripiprazole (partial agonist)

Restless Legs Syndrome (RLS)

Molecular Mechanism

G Protein Signaling

Beta-Arrestin Pathway

• Receptor desensitization
• Beta-arrestin mediated MAPK activation
• Distinct behavioral effects

Receptor Oligomerization

• D2 can form homomers
• D1-D2 heteromers have unique signaling
• Receptor-receptor interactions in disease

Basal Ganglia Circuitry

Indirect Pathway

D2 in Network Context

• D2 neurons receive input from associative/cognitive cortices
• D2 has shorter dendritic spines
• D2 signaling reduces signal-to-noise ratio
• Loss of D2 neurons contributes to hypokinesia

Genetic Variations

Polymorphisms

• Taq1A A1 allele: Associated with reduced D2 receptor density
• C957T: Affects receptor binding affinity
• -141C Ins/Del: Alters promoter activity
• These variants may influence:
• Response to antipsychotics
• Risk of addiction
• [Parkinson's disease](/diseases/parkinsons-disease-disease) progression

Clinical Genetics

• DRD2 variants predict antipsychotic response
• Side effect profiles associated with specific alleles
• Pharmacogenomic testing for clozapine, risperidone

Animal Models

Knockout Studies

• Drd2 knockout mice show hyperactivity
• Impaired presynaptic regulation
• Reward deficits

Transgenic Models

• D2 overexpression: reduced locomotion
• Cre driver lines for cell-specific manipulation

Clinical Considerations

Therapeutic Implications

• D2 agonists for PD motor symptoms
• Antipsychotic-induced hyperprolactinemia
• D2 partial agonists for schizophrenia

Adverse Effects

• Dyskinesia with long-term agonist use
• Impulse control disorders
• Sleep attacks

References

Research Directions

D2-Selective Agents

• Developing biased agonists favoring G protein over beta-arrestin pathways
• Allosteric modulators for greater selectivity
• Bitopic ligands combining orthosteric and allosteric binding

Gene Therapy

• AAV-mediated D2 overexpression in preclinical models
• CRISPR approaches to modulate DRD2 expression

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dopamine Signaling](/mechanisms/dopamine-signaling)
• [Striatum](/brain-regions/striatum)
• [Basal Ganglia](/brain-regions/basal-ganglia)
• [DRD1](/proteins/drd1-protein)

External Links

• [NCBI Gene: DRD2](https://www.ncbi.nlm.nih.gov/gene/1819)
• [UniProt: DRD2](https://www.uniprot.org/uniprot/P14416)

Background

The study of Drd2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: DRD2/SNCA

Pathway Diagram

The following diagram shows the key molecular relationships involving DRD2 Gene discovered through SciDEX knowledge graph analysis: